ERBB2 and triple-negative breast carcinoma: Moreover, HER2-positive invasive breast cancer and triple-negative breast cancer (TNBC, i.e., tumors lacking both HR expression and HER2 overexpression/amplification) must be recognized, as they significantly predict prognosis and treatment response.